When it comes to the next steps for anti-CGRP therapies, we need to discuss the concept of synergism, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
When it comes to the next steps for anti-CGRP therapies, we need to discuss the concept of synergism, said Stephen Silberstein, MD, professor of neurology at Thomas Jefferson University and director of the Headache Center at Jefferson Health.
Transcript:
The American Journal of Managed Care®(AJMC®):What are the next steps for anti-CGRP therapies?
Dr. Silberstein: What we need to do is talk about the concept of synergism. What do I mean by that? If you take drug A, or you're on an antibody, what drug would work to help it give a better result. What we need to do now is take patients who are on antibodies and find out what drugs may give additional benefit. We did that Once. We did a study with patients on topiramate, stable dose, added either propranolol or the propranolol placebo and showed propranolol added nothing. But I can tell you that in a number of the studies patients were on concomitant medication and adding antibodies to their baseline medication resulted in further improvement showing synergism and not antagonism.
AJMC®:Do you have any final thoughts you would like to share?
Dr. Silberstein:I think the biggest question now is whether if you add a botulinum toxin to an antibody is it synergistic. I think we're getting increasing evidence now that the toxins and the antibodies are synergistic. I think Rami Burstein has shown that the botulinum toxin works on the C fibers, antibodies work on the A delta fibers. In our personal experience, we're actually analyzing data now. It's been our bias that patients are attracted to 1 of the 2, you add them together, you get a better result.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More